Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Inclusion Criteria:

• Histologically documented locally advanced and unresectable or metastatic non-smallcell lung cancer with a KRAS G12C mutation

• Measurable disease by RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

Exclusion Criteria:

• Patients with malignancy within the last 2 years as specified in the protocol

• Patients with untreated or unstable brain metastases

• Patients with known hypersensitivity to BBO-8520 or its excipients

• For Cohorts 1b and 2b:

• Patients with a known hypersensitivity to pembrolizumab or its excipients

• Patients with active autoimmune disease of history of autoimmune disease that mightrecur

• Patients with a history of interstitial lung disease/pneumonitis that requiredsteroids, or current interstitial lung disease/pneumonitis

Other inclusion/exclusion criteria may apply